Leonard Zehr, Author at BioTuesdays

Feature

Sigyn Therapeutics hopes to file IDE in Q2 for human studies of Sigyn Therapy

Sigyn Therapeutics (OTC:SIGY) hopes to file in the second quarter this year an investigational device exemption (IDE) with the FDA to initiate human clinical studies of its Sigyn Therapy, a dual-function blood...

February 15, 2022

Feature

Athira Pharma advancing new therapies for neurodegeneration, neuronal health

Athira Pharma (NASDAQ:ATHA) is in late- and mid-stage clinical development of small molecules to restore neuronal health and slow neurodegeneration of diseases, such as Alzheimer’s, Parkinson’s and dementia.

February 8, 2022

Markets

Brookline starts Fusion Pharma at buy; PT $15

Brookline Capital Markets launched coverage of Fusion Pharmaceuticals (NASDAQ:FUSN) with a “buy” rating and $15 price target. The stock closed at $7.53 on Feb. 2. Fusion is a clinical-stage oncology company focused on...

February 2, 2022

Markets

Analysts start Amylyx on strong ALS data and possible regulatory approval

Analysts for SVB Leerink and H.C. Wainwright launched coverage of Amylyx Pharmaceuticals (NASDAQ:AMLX) with “outperform” and “buy” ratings, and price targets of $50 and $35, respectively. The stock closed at $23.18 on...

February 1, 2022

Feature

Zucara awaiting proof-of-concept data to prevent insulin-induced hypoglycemia in people with diabetes

Closely-held Zucara Therapeutics expects to release results in the second quarter of its Phase 1b proof-of-concept study with its once-daily drug candidate, ZT-01, to prevent insulin-induced hypoglycemia, or low blood...

February 1, 2022

Feature

Aravive developing targeted cancer therapeutics to treat metastatic disease

Aravive (NASDAQ:ARAV) is taking a differentiated approach with its lead molecule, batiraxcept, to target inhibition of the GAS6/AXL signaling pathway in several cancer indications.

January 25, 2022

Feature

POINT Biopharma creating platform for next-generation radiopharmaceuticals

POINT Biopharma Global (NASDAQ:PNT) is accelerating the development of precision medicines for the treatment of cancer, with a late- and early-stage pipeline of radiopharmaceuticals, a technology platform for pipeline...

January 18, 2022

Feature

ENDRA’s TAEUS enhancing ultrasound to measure fatty liver disease NAFLD-NASH

ENDRA Life Sciences (NASDAQ:NDRA) has developed a novel assessment tool – Thermo Acoustic Enhanced Ultrasound (TAEUS) – to enhance existing ultrasound systems and provide capabilities that are available with MRI, but at...

January 11, 2022

Feature

Illuminate Health offering pharmacist-led virtual medication management

Closely-held Illuminate Health is leveraging a technology-enabled continuous medication management platform to help patients optimize medications at home to improve treatment adherence and reduce hospitalizations.

January 4, 2022

Feature

Annovis Bio improving information highway of nerve cells to treat AD, PD

Annovis Bio (NYSE:ANVS) is developing a lead drug candidate, ANVS401, to inhibit more than one neurotoxic protein, improving the information highway of nerve cells, known as axonal transport, for the treatment of...

December 14, 2021

Author - Leonard Zehr

Sigyn Therapeutics hopes to file IDE in Q2 for human studies of Sigyn Therapy

Athira Pharma advancing new therapies for neurodegeneration, neuronal health

Brookline starts Fusion Pharma at buy; PT $15

Analysts start Amylyx on strong ALS data and possible regulatory approval

Zucara awaiting proof-of-concept data to prevent insulin-induced hypoglycemia in people with diabetes

Aravive developing targeted cancer therapeutics to treat metastatic disease

POINT Biopharma creating platform for next-generation radiopharmaceuticals

ENDRA’s TAEUS enhancing ultrasound to measure fatty liver disease NAFLD-NASH

Illuminate Health offering pharmacist-led virtual medication management

Annovis Bio improving information highway of nerve cells to treat AD, PD

Subscribe